Cargando…
Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial
BACKGROUND: We have recently completed an evaluation of the safety and feasibility of intravenous delivery of autologous bone marrow in patients with progressive multiple sclerosis (MS). The possibility of repair was suggested by improvement in the neurophysiological secondary outcome measure seen i...
Autores principales: | Rice, Claire M., Marks, David I., Ben-Shlomo, Yoav, Evangelou, Nikos, Morgan, Paul S., Metcalfe, Chris, Walsh, Peter, Kane, Nick M., Guttridge, Martin G., Miflin, Gail, Blackmore, Stuart, Sarkar, Pamela, Redondo, Juliana, Owen, Denise, Cottrell, David A., Wilkins, Alastair, Scolding, Neil J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606493/ https://www.ncbi.nlm.nih.gov/pubmed/26467901 http://dx.doi.org/10.1186/s13063-015-0953-1 |
Ejemplares similares
-
Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II)
por: Rice, Claire M, et al.
Publicado: (2015) -
Reduced cellularity of bone marrow in multiple sclerosis with
decreased MSC expansion potential and premature ageing in vitro
por: Redondo, Juliana, et al.
Publicado: (2017) -
Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis
por: Sarkar, Pamela, et al.
Publicado: (2018) -
Purkinje Cell Pathology and Loss in Multiple Sclerosis Cerebellum
por: Redondo, Juliana, et al.
Publicado: (2014) -
Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis
por: Redondo, Juliana, et al.
Publicado: (2018)